New TB diagnostics
-
According to the World Health Organization (WHO), tuberculosis is one of the ten most common causes of death in children under the age of five. One of the main reasons for this is that the disease is often not diagnosed correctly and in good time. This particularly affects regions with few resources. Available tests are too expensive, complex or technically complicated. There is an urgent need for new, child-friendly test procedures that can be carried out using simple samples (e.g. saliva). To change this, the "New TB Diagnostics" research group, led by PD Dr. med. Norbert Heinrich and co-led by Dr. med. Laura Olbrich, DPhil, is evaluating new diagnostics. To this end, studies on new TB diagnostics are prepared, conducted and evaluated.
One focus is RaPaed-AIDA-TB (Rapid and Accurate Diagnosis of Paediatric TB - An AIDA (Assessment of Innovative Diagnostic and Algorithms for Early and Sensitive Detection of Acute TB)), one of the largest TB diagnostic studies in children. The ERASE-TB (Early risk assessment in TB contacts by the use of new tests) study aims to establish the early diagnosis of developing tuberculosis in TB contacts using new diagnostic assays. Results of the project were published in October 2023 in the journal The Lancet Infectious Diseases (see LMU news release, 31.10.2023).
The results of the research will also be incorporated into the development of TB diagnostic recommendations of the World Health Organization (WHO), Dr. med. Laura Olbrich, DPhil, took part in a consultative meeting with WHO representatives in Osaka, Japan.
The research group is also working, for example as part of the UNITE4TB research consortium, on the development and clinical evaluation of diagnostic biomarkers for personalized, shortened tuberculosis treatment (see also TB drug development research group). -
ManagementPD Dr. med. Norbert HeinrichSenior Physician, Unit Head, Tuberculosis Diagnostics & Drug DevelopmentDr. med. Laura Olbrich, DPhilCo-Head of new TB Diagnostics, Sponsor Medical ExpertTeamDr. Akshita Gupta, MD, PhDPostdoctoral Fellow DECIDE-TBFoczlbgeXYföbgvim ful_vfiuyziusmiProfessor Katharina KranzerLondon School of Hygiene & Tropical MedicineLeyla Larsson, MScPhD candidate in Epidemiology and Public HealthäiјägtäDgpccüuvims:ful,rvfiuyziWu miUrsula Panzner, MScScientific Program Manager, ERASE-TBAlia RazidClinical Program Coordinator, Master StudentFälgsBgßlmviSmYn; ful_vfiuyziusmiVerena CzirnichFinancial Administration, Scientific Administrator DZIF+49 (0)89 4400-59838Doctoral/PhD studentscand. med. Lisa KüblerAlfred Mfinanga, MDPhD StudentDenise Banze, MDPhD Student
-
Ongoing projects
Decide TBThe Decide-TB project is an implementation research project aiming to improve the diagnosis and management of tuberculosis in children by using treatment decision algorithms (TDAs).
These algorithms will help clinicians to make rapid and consistent decisions for the treatment of tuberculosis in children.
About the Decide TB project
Rapid and accurate diagnosis of paediatric tuberculosis (RaPaed TB)RaPaed is one of the largest cohort and diagnostic studies ever conducted in the field of pediatric tuberculosis. It is funded by the European-African Cooperation European & Developing Countries Clinical Trials Partnership (EDCTP) and the German Center for Infection Research (DZIF).
At the heart of the project is a diagnostic validation study, which is being carried out together with local partners in five countries. Four sites are located in Africa (South Africa, Tanzania, Mozambique, Malawi) and one in India. The study will examine a total of 10 diagnostic approaches and evaluate eight new diagnostic tests. The performance of the tests will be compared with the reference standard for diagnostic validation studies for children.
The RaPaed-AIDA-TB project brings together experienced academic health centers and a center for clinical studies at LMU with academic test developers and large industrial partners. The tests are established through platforms that enable point-of-care testing or testing in local hospitals with shortened referral times. With the aim of strengthening healthcare structures and research worldwide, RaPaed-AIDA-TB also contributes to the local development of expertise in the diagnosis of childhood tuberculosis and the training of African researchers.
News about the project
The RaPaed project consortium
Coordinator: LMU Klinikum München
Clinical study centers
- National Institute for Medical Research (NIMR - MMRC), Mbeya, Tanzania
- Instituto Nacional de Saúde (INS), Mozambique
- University of Malawi College of Medicine (CoM), Blantyre, Malawi
- University of Cape Town Lung Institute (UCTLI), Cape Town, South Africa
- Christian Medical College (CMC), Vellore, India
Consortium and project partners- LMU, Munich
- Foundation for Innovative New Diagnostics (FIND), Switzerland
- University of Melbourne, Australia
- Stellenbosch University, South Africa
- Karolinska Institute, Sweden
- Research Center Borstel, Germany
- NTP Tanzania, NTP, Mozambique
- MoH, Malawi
- OVG, Oxford University, UK
Industry partner
- Beckman Coulter, Inc.
- Cepheid
Financing
RaPaed-AIDA-TB is funded by the European & Developing Countries Clinical Trials Partnership (EDCTP; RIA2016MC -1623) and the German Center for Infection Research (DZIF)
Early Risk Assessment in TB contacts by new diagnostic tests (ERASE-TB)In the ERASE-TB (Early risk assessment in TB contacts by the use of new tests) study, the early diagnosis of developing tuberculosis in TB contacts will be established using new diagnostic assays. In 2021, the international research team began recruiting up to 2,100 contact persons with infectious pulmonary tuberculosis for the study. The study is being conducted with local partners in Tanzania, Mozambique and Zimbabwe and will be followed up for up to 2 years.
ERASE-TB Newsletter
Completed projects
Evaluation of improved screening algorithms in refugees using new diagnostics (Refuscreen TB) -
The RaPaed project consortium
Overview RaPaed consortium partners and organization chart
Coordinator: LMU Klinikum MünchenClinical study centers
- National Institute for Medical Research (NIMR - MMRC), Mbeya, Tanzania
- Instituto Nacional de Saúde (INS), Mozambique
- University of Malawi College of Medicine (CoM), Blantyre, Malawi
- University of Cape Town Lung Institute (UCTLI), Cape Town, South Africa
- Christian Medical College (CMC), Vellore, India
Consortium and project partners- LMU, Munich
- Foundation for Innovative New Diagnostics (FIND), Switzerland
- University of Melbourne, Australia
- Stellenbosch University, South Africa
- Karolinska Institute, Sweden
- Research Center Borstel, Germany
- NTP Tanzania, NTP, Mozambique
- MoH, Malawi
- OVG, Oxford University, UK
Industry partner
- Beckman Coulter, Inc.
- Cepheid
ERASE-TB project consortium
-
Promotion
RaPaed-AIDA-TB
RaPaed-AIDA-TB is funded by the European & Developing Countries Clinical Trials Partnership (EDCTP; RIA2016MC -1623) and the German Center for Infection Research (DZIF).
ERASE-TB
The ERASE-TB project is part of the EDCTP-2 program supported by the European Union.